Emergent BioSolutions (NYSE:EBS) Lowered to “Hold” Rating by StockNews.com

StockNews.com lowered shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research report released on Wednesday.

A number of other research analysts have also commented on EBS. Benchmark lifted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw restated a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Performance

Shares of EBS opened at $8.88 on Wednesday. The company’s 50 day simple moving average is $8.69 and its 200-day simple moving average is $8.17. The firm has a market cap of $481.15 million, a PE ratio of -2.17 and a beta of 1.57. Emergent BioSolutions has a 12-month low of $1.42 and a 12-month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Hedge Funds Weigh In On Emergent BioSolutions

Institutional investors have recently bought and sold shares of the company. State Street Corp boosted its holdings in shares of Emergent BioSolutions by 864.7% in the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP purchased a new stake in Emergent BioSolutions in the 3rd quarter valued at approximately $9,296,000. American Century Companies Inc. boosted its holdings in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after purchasing an additional 623,201 shares in the last quarter. Vanguard Group Inc. increased its position in Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after purchasing an additional 436,911 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in shares of Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after buying an additional 316,700 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.